Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

FDA Approves Abbott sNDA

August 18, 2010 6:58 am | News | Comments

Abbott announced that the U.S. Food and Drug Administration approved the supplemental New Drug Application for CREON Delayed-Release Capsules that now includes dosing guidance specific to patients with exocrine pancreatic insufficiency.


NephRx's NX001 Granted Orphan Drug Status

August 18, 2010 6:50 am | News | Comments

NephRx Corporation announced that the U.S. Food and Drug Administration has granted orphan drug designation to its lead product NX001 for the prevention of delayed graft function in renal transplant recipients.


Shire Pulls ProAmatine After FDA Letter

August 18, 2010 6:47 am | by Matthew Perrone | News | Comments

Shire PLC said it will pull a blood-pressure drug off the market following warnings from federal regulators who said the drug has not been proven effective.


Transfer Plasmid

August 17, 2010 7:40 am | Product Releases | Comments

Oxford Expression Technologies, a specialist provider of baculovirus-based protein expression solutions, launches pOET3, a novel baculovirus transfer plasmid for improved expression of glycosylated, secreted, and membrane-targeted proteins.


Chronix Expands Biomarker Development

August 17, 2010 7:16 am | News | Comments

Chronix Biomedical reported that it has significantly expanded and accelerated its biomarker development capabilities with the installation of Germany’s first state-of-the-art high-throughput DNA mass sequencer at the University of Göttingen.


Bioo Scientific Chooses Eureka Genomics for NGS

August 17, 2010 6:48 am | News | Comments

After evaluating multiple service providers, Bioo Scientific chose Eureka Genomics as its next-generation sequencing service provider based on their extensive sequencing experience, quick turnaround times, and strong bioinformatics support.


Antidepressant Helps Treat Menopausal Depression

August 17, 2010 6:26 am | News | Comments

A recently released double-blind trial showed that the antidepressant Pristiq can alleviate symptoms of major depression in women experiencing or about to experience menopause.


Researchers Develop MRSA-Killing Paint

August 17, 2010 6:21 am | News | Comments

Building on an enzyme found in nature, researchers have created a nanoscale coating for surgical equipment, hospital walls, and other surfaces which safely eradicates methicillin resistant Staphylococcus aureus, the bacteria responsible for antibiotic resistant infections.


Team Maps Epigenetic Changes in Stem Cells

August 17, 2010 6:16 am | News | Comments

Having charted the occurrence of a common chemical change that takes place while stem cells decide their fates and progress from precursor to progeny, a team of scientists has produced the first-ever epigenetic landscape map for tissue differentiation.


New Targets Discovered For Anti-Angiogenesis Drugs

August 17, 2010 6:13 am | News | Comments

A new study describes how a carbohydrate-binding protein, galectin-3, promotes angiogenesis, the growth of new blood vessels. Targeting the protein, scientists identified two approaches that significantly reduced angiogenesis in mice.


Pfizer Granted Approval For New XYNTHA Delivery Method

August 17, 2010 6:04 am | News | Comments

Pfizer Inc. announced that the U.S. Food and Drug Administration has granted approval of the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients.


FDA Questions Expanded Cymbalta Use

August 17, 2010 5:52 am | by Matthew Perrone | News | Comments

Federal health scientists are questioning whether the antidepressant Cymbalta is safe and effective enough to be approved for use against chronic pain.


Feds Push to Withdraw ProAmatine

August 17, 2010 5:50 am | by Matthew Perrone | News | Comments

Federal health regulators are pushing to withdraw a blood pressure drug that has been on the market for 14 years in spite of the manufacturer's failure to submit evidence that it actually helps patients.


Berkshire Hathaway Ups Stake In J & J

August 17, 2010 5:47 am | by Josh Funk | News | Comments

Warren Buffett's Berkshire Hathaway Inc. has partially rebuilt the stake in Johnson & Johnson he reduced over the past two years to raise cash for other investments.


Lilly Halts Disappointing Alzheimer's Treatment

August 17, 2010 5:43 am | News | Comments

Drugmaker Eli Lilly and Co. has stopped developing a potential Alzheimer's disease treatment in late-stage testing after patients taking the drug fared worse than those on a placebo.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.